《Drug Resistance in Leukemia and Lymphoma》是一本圖書，作者是Kaspers, G. J.; Pieters, R.; Veerman, A. J. P.
19. Ji M,Li J, Yu H, Ma D, Ye J, Sun X, Ji C. Simultaneous targeting of MCL1 and MDR1 asa novel strategy to overcome drug resistance in human leukemia. Br J Haematol.2009; 145(5): 648-56.20. Dong C, Ji M, Ji C. Micro-RNAs and theirpotential target genes in leukemia ...
[8] Chao-Hua Deng, Qiuping Zhang(通訊作者). Leukemia stem cells in drug resistance and metastasis Chin Med J., 2010;123(7):954-960 專利：一種重組免疫毒素CCL25-PE38基因及製備方法和套用，申請號：201110001125.2（張秋萍，胡義，張莉）發現了趨化性細胞因子受體9（CCR9）及其配體CCL25與急性T淋巴...
Li, Yan Li, Yi Zhang, Ke Wang, Xia Yuan, Jing Jin, Yan Zhang, Zhanzhu Liu, Xiaoguang Chen*. A novel bisindolymaleimide derivative (WK234) in hibits proliferation and induces apoptosis through the protein kinase C b pathway, in chronic myelogenous leukemia K562 cells. Leukemia & Lymphoma...
首次發現天花粉蛋白(TCS)有抗白血病和淋巴瘤的作用,TCS抗愛滋病的效果可能與其選擇性的細胞毒性有關。首次以猴愛滋病病毒(SRV)為對象，建立了適用於無P3實驗室條件時篩選抗愛滋病藥物的體外實驗模型。建立了完整一套體外的抗HIV藥物篩選和研究方法，並在此基礎上篩選了數百種動植物來源的天然化合物，從動植物和海洋...
裴正康，1951年8月出生於中國台灣，美國國籍 ，台灣中央研究院院士、中國工程院外籍院士，美國聖述德兒童研究醫院腫瘤系主任。1976年裴正康獲得台灣大學醫學博士學位；1977年在美國 St. Jude兒童研究醫院從事兒童白血病的研究和治療；2014年，當選台灣中央研究院院士；2015年當選為中國工程院外籍院士。裴正康長期從事兒童腫瘤...
3. LLS，10/01/10 – 09/30/13 Targeting NEK2 in MM to Overcome Drug-resistance，Direct Costs: $540,000, Total Costs: $600,000Leukemia Lymphoma Society，Role: Principal Investigator 4. R01，CA115399， 07/01/07 – 06/30/12 Gene Expression Profiling vs MRD Assessment in Myeloma National ...
4、Shuqing Lv, Zhilong Chen, Jianmin Yang, et al. Overexpression of the PSMB5 gene contributes to bortzomib resistance in T-lympoblastic lymphoma/ leukemia cells derived from Jurkat line. Experimental Hematology, 2008, 36 (10): 1278-1284.5、Deng Kui, Chen Zhi-Long, Zhou Xing-Ping, et ...
48. Hu K, Gu Y, Lou L, Liu L, Hu Y, Wang B, Luo Y, Shi J, Yu X, Huang H*. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.J Hematol Oncol. 2015 Jan 27;8(1):1.49. Gorin NC, Labopin M...
（16）Fu Y, Gao X, Yu X, Liu X, Du Q*.Ephrin type-B receptor 4 is an essential mediator in drug-resistance of acute myeloid leukemia cells to Adriamycin.J Exp Ther Oncol.2018-11-12;2018 Nov;12(4):249-259.（IF:3.561）（17）Liu H, Wang C, Wang P, Liu N*, Du Q*. A ...
36. Zhong YJ, Chen BA*,Feng JF, Cheng L, Li Y, Qian J, Ding JH, Gao F, Xia GH, Chen N, Lu Z. Theassociations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomesin patients with acute myeloid leukemia. Leuk Lymphoma. 2010; 51(6):1115-20.37. Zhu XL, Zhang...
B, Gong Y, Lee J, Konopleva M, Andreeff M, Arlinghaus RB, Cai Z, Fang B, Shen H, Han X, Hirsch-Ginsberg CF, Gao X, Paranjape AN, Mani SA, Clise-Dwyer K, Sun X. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. ...
10. Autocrine and possible intracrine regulation of HL-60 cell proliferation by macrophage colony-stimulating factor，《Leukemia Research》25:1107,2001 11. Efficacy of anti-CD20chimericFab’ fragment on proliferation of B lymphoma cells. 《Chinese Science Bulletin》46(14):1182,2001 12. Eff...
